Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

FDA sets review date for new Opdivo lung cancer treatment

EditorEmilio Ghigini
Published 07/02/2024, 11:40 pm
© Reuters.
BMY
-

PRINCETON, N.J. - The U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics Application (sBLA) for Opdivo (nivolumab), an immunotherapy drug, in combination with chemotherapy for the treatment of a specific type of lung cancer. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of October 8, 2024, to complete its review.

Opdivo is being evaluated for its potential use in the perioperative treatment of resectable stage IIA to IIIB non-small cell lung cancer (NSCLC). The application is based on results from the Phase 3 CheckMate -77T trial, which showed a statistically significant improvement in event-free survival (EFS) for patients treated with the Opdivo-based regimen compared to the current standard of neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo.

The trial also assessed secondary endpoints, including pathologic complete response (pCR) and major pathologic response (MPR), and found benefits in these areas as well. The safety profile of the perioperative regimen was consistent with previous studies in NSCLC, and no new safety signals were identified.

Lung cancer remains the leading cause of cancer deaths globally, with NSCLC being the most common type, accounting for up to 84% of cases. Despite surgical advances, a significant number of patients experience disease recurrence, highlighting the need for new treatment options that can be administered before (neoadjuvant) and/or after surgery (adjuvant) to improve long-term outcomes.

Opdivo, a programmed death-1 (PD-1) immune checkpoint inhibitor, is designed to harness the body’s immune system to help restore anti-tumor immune response. It has shown efficacy benefits in various cancer treatments, including lung, bladder, esophageal/gastroesophageal junction cancer, and melanoma.

Bristol Myers (NYSE:BMY) Squibb, the company behind Opdivo, is committed to expanding treatment options for cancer patients and improving their outcomes. The acceptance of the sBLA by the FDA represents a significant step in potentially providing a new treatment regimen for patients with resectable non-small cell lung cancer.

This news is based on a press release statement from Bristol Myers Squibb. The company's shares are traded on the New York Stock Exchange under the ticker symbol NYSE:BMY.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.